Survodutide is a dual glp-1/glucagon receptor agonist with a development status of "phase 3 clinical trials". The Institute rates the strength of its published evidence as moderate. A dual agonist pairing GLP-1 activity with glucagon receptor agonism, studied for obesity and for liver-fat endpoints in MASH.
The distinction that matters most when reading about Survodutide is between what has been demonstrated and what has been proposed. Mechanistic plausibility is not evidence of effect, and a compound can have a well-characterised receptor interaction while producing no measurable clinical benefit. That gap is where most of the confusion in this space lives.
Sample sizes in the Survodutide literature are small enough that individual studies should be read as hypothesis-generating rather than conclusive. Effect sizes reported in small trials are systematically inflated, and the pattern is well documented across pharmacology generally.
The Institute has independently tested 4 Survodutide samples from 3 companies. 75% met their label claims on purity and content. Measured purity ranged from 98.2% to 99.4%, averaging 98.7%. Every specimen is published in full, including the laboratory that ran it.
The Peptide Institute is an independent research institute. We do not sell products, we do not accept vendor sponsorship, and we publish results that reflect badly on companies as readily as results that do not.
